| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary biological target of zifanocycline is the bacterial 30S ribosomal subunit. By binding to this subunit, it prevents the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site, thereby inhibiting the elongation phase of protein synthesis. This mechanism is common to all tetracycline antibiotics. The aminomethylcycline modification enhances its activity against bacteria that have acquired tetracycline-specific resistance mechanisms, such as efflux pumps and ribosomal protection proteins. Its broad-spectrum activity and oral bioavailability make it a promising antibiotic for clinical use.
|
|---|---|
| ln Vitro |
Zifanocycline (KBP-7072) exhibits minimum inhibitory concentration (MIC90) values of less than 1 μg/ml against several pathogens, encompassing both common and uncommon pathogens linked to community-acquired bacterial pneumonia (CABP)[1].
In vitro, zifanocycline exhibits a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria. It is active against many multidrug-resistant pathogens, including MRSA, vancomycin-resistant enterococci (VRE), and multidrug-resistant Acinetobacter baumannii. The minimum inhibitory concentrations (MICs) against these pathogens are typically in the low microgram per milliliter range. The specific MIC values vary depending on the bacterial strain and the testing method used. Its in vitro activity is evaluated using standard broth microdilution methods according to CLSI guidelines. |
| ln Vivo |
KBP-7072 showed a linear PK profile in Sprague-Dawley (SD) rats, beagle dogs, and CD-1 mice following the administration of single oral, IV, and multiple oral doses. Between 12% and 32% of the oral bioavailability was found. There was a range of 0.5 to 4 hours for the mean time to maximum concentration (T max) and roughly 6 to 11 hours for the mean half-life. When oral dosages were given to fed animals, the maximum plasma concentration (C max) and the area under the concentration-time curve (AUC) were much lower than when dosing was done on fasting animals. KBP-7072's mean bound fractions in mouse, rat, dog, monkey, and human plasma were, respectively, 77.5%, 69.8%, 64.5%, 69.3%, and 69.2%[1]. When used against certain methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) S. bacteria, KBP-7072 demonstrates dose-dependent, strong efficacy. aureus strains in a neutropenic murine pneumonia infection model within the dose range (0.25 to 64 mg/kg/6 h) that was investigated[2].
In vivo, zifanocycline has demonstrated dose-dependent potent activity in animal models of infection. In a neutropenic murine pneumonia infection model, it showed efficacy against both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus. It has also shown efficacy against Acinetobacter baumannii in a neutropenic murine thigh infection model. The in vivo efficacy is correlated with its pharmacokinetic properties, and dose-fractionation studies have been used to identify the pharmacodynamic index (e.g., AUC/MIC) that best predicts efficacy. |
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for zifanocycline involves measuring its binding to the bacterial 30S ribosomal subunit. This can be performed using a radioligand binding assay with purified 30S subunits and a radiolabeled tetracycline derivative (e.g., [3H]tetracycline). The compound's ability to displace the radioligand is measured. The Kd or Ki value is calculated from the competition curve. This assay characterizes the compound's affinity for the ribosome and its potential to overcome resistance mechanisms that target the ribosome.
|
| Cell Assay |
The in vitro cellular assay for zifanocycline is the determination of the minimum inhibitory concentration (MIC) against various bacterial strains. This is typically performed using the broth microdilution method according to CLSI guidelines. Bacteria are grown in a 96-well plate in the presence of serial two-fold dilutions of the antibiotic. After an incubation period (e.g., 16-20 hours), the lowest concentration of the antibiotic that inhibits visible bacterial growth is recorded as the MIC. This assay is used to evaluate the susceptibility of different bacterial clinical isolates to zifanocycline.
|
| Animal Protocol |
The in vivo animal experiment workflow for zifanocycline typically involves the use of mouse models of infection. For a neutropenic murine thigh infection model, mice are rendered neutropenic with cyclophosphamide and then infected with a bacterial strain (e.g., Acinetobacter baumannii) via intramuscular injection into the thigh. The antibiotic is administered orally at various doses. The bacterial load in the thigh muscle is quantified after 24 hours to assess the efficacy. For a pneumonia model, mice are infected intranasally with the bacteria, and the antibiotic is administered orally. The bacterial load in the lungs and the survival rate are the primary endpoints.
|
| References |
[1]. Tan X, et al. Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models. Antimicrob Agents Chemother. 2020;64(6):e00488-20. Published 2020 May 21.
[2]. Lepak AJ, et al. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2019;63(3):e02404-18. Published 2019 Feb 26. |
| Molecular Formula |
C29H36N4O7
|
|---|---|
| Molecular Weight |
552.618747711182
|
| Exact Mass |
552.258
|
| CAS # |
1420294-56-9
|
| Related CAS # |
Zifanocycline TFA
|
| PubChem CID |
71243332
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.6
|
| tPSA |
168
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
40
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN5CC6CC6C5)N(C)C
|
| InChi Key |
LBKXOQRVWDAQSX-OMBSCLNISA-N
|
| InChi Code |
InChI=1S/C29H36N4O7/c1-31(2)18-8-15(11-33-9-13-5-14(13)10-33)23(34)20-16(18)6-12-7-17-22(32(3)4)25(36)21(28(30)39)27(38)29(17,40)26(37)19(12)24(20)35/h8,12-14,17,22,34-35,38,40H,5-7,9-11H2,1-4H3,(H2,30,39)/t12-,13?,14?,17-,22-,29-/m0/s1
|
| Chemical Name |
(4S,4aS,5aR,12aR)-9-(3-azabicyclo[3.1.0]hexan-3-ylmethyl)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8096 mL | 9.0478 mL | 18.0956 mL | |
| 5 mM | 0.3619 mL | 1.8096 mL | 3.6191 mL | |
| 10 mM | 0.1810 mL | 0.9048 mL | 1.8096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.